At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
pazopanibdrug
Likely dose
pazopanib 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
In Brief
A Phase 2 clinical trial evaluating pazopanib for Chondrosarcoma and Metastatic Chondrosarcoma. Completed, enrolled 47 participants across 7 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChondrosarcoma, Metastatic Chondrosarcoma
CountriesUnited Kingdom, United States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedApr 2011
Primary CompletionFeb 2018
TodayJul 2026
First PostedApr 7, 2011
Enrollment StartApr 1, 2011
Primary CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 15.2 years ago
Interventions
pazopanibdrug
Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.